Biotech RadarJobs updated

COMPANY

BioAtla, Inc.

HQ: San Diego, CA source · bioatla.com ↗ · West Coast

Clinical Phase 2

Also known as BioAtla · 8 sources

BioAtla, Inc. is listed on ClinicalTrials.gov as the lead sponsor of 6 studies; the most recently updated is “A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck” (Phase 2, completed), in Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck. From public records Source · Oct 12, 2026

Keywords: Cancer Head and Neck Cancer Non-Small-Cell Lung Cancer Melanoma Squamous Cell Carcinoma of Head and Neck Recurrent Squamous Cell Carcinoma of the Head and Neck Metastatic Squamous Cell Carcinoma of the Head and Neck Advanced Adenocarcinoma Undifferentiated Pleomorphic Sarcoma Myxofibrosarcoma NSCLC Triple Negative Breast Cancer BA3182 BA3071

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

$9.2MRaised (2 yrs)6Trials (company is sponsor)1NIH grants

Timeline

  1. Raise Follow-on offering — Registered direct: $9.2M (total, as published), announced Dec 20, 2024. Source: SEC filing. source ↗
  2. Trial start 1: Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. source ↗
  3. Trial start 2: A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck source ↗
  4. Trial start 1: A Phase 1/2 Study of BA3071 in Patients With Solid Tumors source ↗
  5. Trial start Phase 2: CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC source ↗
  6. Trial start Phase 1/Phase 2: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) source ↗
  7. Trial start Phase 1/Phase 2: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $9.2M. Last 2 years.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT05271604A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck2CompletedDec 13, 2022Sep 22, 2025 (actual)
NCT04681131CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLCPhase 2CompletedMar 17, 2021Jul 9, 2025 (actual)
NCT05808634Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.1RecruitingJul 14, 2023Sep 15, 2028 (estimated)
NCT03425279CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With SarcomaPhase 1/Phase 2CompletedFeb 15, 2018Jan 8, 2025 (actual)
NCT05180799A Phase 1/2 Study of BA3071 in Patients With Solid Tumors1Active, not recruitingAug 3, 2022Mar 19, 2025 (actual)
NCT03504488CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)Phase 1/Phase 2CompletedJun 27, 2018Dec 30, 2024 (actual)

NIH awards 1

Annual award amounts. Total $220K.

Feedback